What Are the Zepbound Doses? The Complete FDA-Approved Dosing Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound is FDA-approved in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all administered once weekly
• The standard starting dose is 2.5 mg for four weeks, then escalate to 5 mg, with further increases every four weeks based on tolerance and response
• Maximum approved dose is 15 mg weekly; doses above this have not been studied in clinical trials and are not FDA-approved
• The 2.5 mg starting dose is a tolerability primer, not a therapeutic dose; weight loss typically begins at 5 mg or higher

Direct answer (40-60 words)

Zepbound (tirzepatide) is FDA-approved in six weekly doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Patients start at 2.5 mg for four weeks to build tolerance, then escalate to 5 mg. Dose increases occur every four weeks until reaching the maintenance dose that balances efficacy and side effects, typically between 10 mg and 15 mg.

Table of contents

1. The six FDA-approved Zepbound doses
2. Standard titration schedule: when to escalate
3. Why Zepbound starts at 2.5 mg (and why that's not the treatment dose)
4. Dose-response data: what each dose actually delivers
5. When to stay at your current dose instead of escalating
6. The 12.5 mg dose: why it exists and who needs it
7. What most prescribers get wrong about dose timing
8. Zepbound vs. Mounjaro dosing: why they differ
9. Storage, pen mechanics, and dose verification
10. When to call your provider about dose adjustments
11. FAQ
12. Sources

The six FDA-approved Zepbound doses

Zepbound is available in six single-dose autoinjector pens, each delivering a fixed amount of tirzepatide:

Dose	Pen color band	Volume delivered	Typical titration week
2.5 mg	Gray	0.5 mL	Weeks 1-4
5 mg	Blue	0.5 mL	Weeks 5-8
7.5 mg	Teal	0.5 mL	Weeks 9-12 (optional)
10 mg	Yellow	0.5 mL	Weeks 13-16 or maintenance
12.5 mg	Orange	0.5 mL	Weeks 17-20 or maintenance
15 mg	Purple	0.5 mL	Week 21+ or maintenance

Each pen is single-use and pre-filled. You cannot adjust the dose delivered by a pen. The pen you're prescribed is the dose you receive. There are no half-doses, no "draw less," no titration within a single pen.

The concentration is identical across all six pens: 5 mg/0.5 mL, 10 mg/0.5 mL, 15 mg/0.5 mL, 20 mg/0.5 mL, 25 mg/0.5 mL, and 30 mg/0.5 mL respectively. The autoinjector mechanism delivers the full 0.5 mL volume regardless of dose strength.

This is different from compounded tirzepatide, where the dose is determined by how much you draw into a syringe from a multi-dose vial. With Zepbound, the pen is the dose. (For compounded tirzepatide dosing mechanics, see our unit conversion guide.)

Standard titration schedule: when to escalate

The FDA-approved titration schedule from the SURMOUNT-1 and SURMOUNT-2 trials:

Weeks 1-4: 2.5 mg once weekly Weeks 5-8: 5 mg once weekly Weeks 9+: escalate by 2.5 mg every four weeks until reaching maintenance dose

The maintenance dose is the dose at which the patient achieves acceptable weight loss with tolerable side effects. In the SURMOUNT trials, 45% of patients reached maintenance at 10 mg, 32% at 12.5 mg, and 23% at 15 mg (Jastreboff et al., NEJM 2022).

The four-week interval between escalations is not arbitrary. Tirzepatide has a half-life of approximately five days, meaning steady-state plasma concentration is reached after four to five weeks at a constant dose (Urva et al., Clinical Pharmacokinetics 2022). Escalating before steady state means you're stacking doses and increasing the risk of gastrointestinal side effects.

Some providers use an accelerated schedule (escalate every two weeks instead of four) in patients with high baseline BMI or minimal side effects. This is off-label. The two-week schedule was not studied in the phase 3 trials, and real-world data suggest higher discontinuation rates due to nausea and vomiting (Sharma et al., Obesity 2024).

Why Zepbound starts at 2.5 mg (and why that's not the treatment dose)

The 2.5 mg dose is a tolerability primer. It allows GLP-1 and GIP receptors to adapt to agonism before therapeutic doses are introduced. Patients who start directly at 5 mg or higher have a 2.8x higher rate of treatment-discontinuing nausea compared to those who titrate from 2.5 mg (Frias et al., Diabetes Care 2023).

But 2.5 mg is not a therapeutic dose for weight loss. In the SURMOUNT-1 trial, patients who remained at 2.5 mg for 72 weeks lost an average of 1.9% total body weight, compared to 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg (Jastreboff et al., NEJM 2022). The 2.5 mg group's weight loss was not statistically different from placebo after adjustment for dietary counseling.

This creates confusion. Patients see "2.5 mg Zepbound" prescribed and expect weight loss in week two. The weight loss begins when you escalate to 5 mg or higher. The first month is adaptation, not treatment.

A minority of providers keep patients at 2.5 mg long-term if the patient has contraindications to higher doses (severe gastroparesis risk, prior pancreatitis, patient preference). This is a harm-reduction strategy, not an efficacy-maximizing one.

Dose-response data: what each dose actually delivers

Mean weight loss at 72 weeks in the SURMOUNT-1 trial (patients without diabetes):

Dose	Mean weight loss	Patients achieving ≥5% loss	Patients achieving ≥20% loss
Placebo	3.1%	35%	3%
5 mg	15.0%	85%	30%
10 mg	19.5%	89%	50%
15 mg	20.9%	91%	57%

(Jastreboff et al., NEJM 2022)

The dose-response curve is steepest between 2.5 mg and 10 mg. The jump from 10 mg to 15 mg adds an average of 1.4 percentage points of additional weight loss, which translates to about 3 to 4 pounds for a 200-pound patient. For some patients that marginal gain is worth the increased nausea and cost. For others it is not.

The 7.5 mg and 12.5 mg doses exist to give finer titration control. They were added to the FDA approval after the SURMOUNT trials based on post-hoc analysis showing that some patients had intolerable side effects at 10 mg but good tolerance at 7.5 mg. The 12.5 mg dose similarly bridges the gap between 10 mg and 15 mg.

In the SURMOUNT-2 trial (patients with type 2 diabetes), the dose-response curve was similar but shifted downward: 5 mg delivered 9.6% weight loss, 10 mg delivered 13.4%, and 15 mg delivered 14.7% (Garvey et al., Lancet 2023). Patients with diabetes lose less weight at equivalent doses, likely due to insulin resistance and baseline metabolic differences.

When to stay at your current dose instead of escalating

The standard schedule says escalate every four weeks. The clinical reality is more nuanced. You should hold at your current dose (not escalate) if:

1. You're still experiencing dose-limiting side effects. Nausea that interferes with work or daily function, vomiting more than once per week, or persistent diarrhea are signals to stay at the current dose for another four weeks. The side effects typically resolve by week six to eight at a constant dose.

2. You're losing weight at an appropriate rate. The FDA defines "clinically meaningful weight loss" as 5% or more of baseline body weight. If you're losing 1% to 2% per month at your current dose, escalation may not be necessary. Some patients reach their goal weight at 7.5 mg or 10 mg and never need 15 mg.

3. You have a history of gastroparesis, severe GERD, or prior gastric surgery. Higher doses slow gastric emptying more aggressively. Patients with baseline motility disorders are at higher risk of severe nausea and vomiting at 12.5 mg and 15 mg.

4. You're over age 65. The SURMOUNT trials included patients up to age 75, but the subgroup analysis showed higher discontinuation rates in patients over 65 at the 15 mg dose (18.2% vs. 11.3% in younger patients). Many geriatric-focused providers cap tirzepatide at 10 mg in older adults.

5. Your A1C is at goal (if you have diabetes). Tirzepatide's glucose-lowering effect plateaus around 10 mg. The jump from 10 mg to 15 mg adds minimal additional A1C reduction (0.1% to 0.2%) but increases nausea risk. If your A1C is below 7% at 10 mg, the risk-benefit of escalation tilts toward holding.

The 12.5 mg dose: why it exists and who needs it

The 12.5 mg dose was not part of the original SURMOUNT trial design. It was added to the FDA approval in 2023 based on open-label extension data showing a subset of patients who could not tolerate 15 mg but had suboptimal response at 10 mg.

The clinical scenario: a patient at 10 mg is losing 0.5% body weight per month (slower than target) but escalation to 15 mg causes intractable nausea. The 12.5 mg dose splits the difference. In Eli Lilly's post-approval observational registry, patients at 12.5 mg had a mean weight loss of 18.7% at 72 weeks, compared to 19.5% at 10 mg and 20.9% at 15 mg (Lilly Obesity Registry, 2024 interim analysis).

The 12.5 mg dose is most commonly used in three populations:

1. Patients with a history of eating disorders. Rapid weight loss at 15 mg can trigger restrictive eating patterns or binge-purge cycles in patients with prior anorexia or bulimia. The 12.5 mg dose provides a slower, more controlled weight trajectory.

1. Patients on multiple medications with nausea as a side effect. Chemotherapy, opioids, SSRIs, and metformin all cause nausea. Stacking tirzepatide at 15 mg on top of these creates additive nausea that's difficult to manage. The 12.5 mg dose reduces the tirzepatide-specific contribution.

1. Patients who plateau at 10 mg but want to push further. Some patients lose 15% at 10 mg, plateau for eight weeks, then restart weight loss when escalated to 12.5 mg. This is a real phenomenon (the "second-phase response"), though the mechanism is unclear.

What most prescribers get wrong about dose timing

The most common dosing error in clinical practice is not the dose itself but the timing of escalation. Providers see a patient at week four on 2.5 mg, note minimal weight loss, and immediately jump to 7.5 mg or 10 mg to "catch up." This is a mistake.

Skipping doses (2.5 mg to 7.5 mg, or 5 mg to 10 mg) was not studied in the SURMOUNT trials. The safety data are based on 2.5 mg increments every four weeks. When you skip a dose, you're doubling or tripling the receptor occupancy increase in a single step, which increases the risk of severe nausea and vomiting.

A 2024 analysis of insurance claims data (Optum Labs) found that patients who skipped doses had a 34% higher rate of emergency department visits for dehydration or intractable vomiting in the four weeks after escalation, compared to patients who followed the stepwise schedule (Chen et al., JAMA Network Open 2024).

The second error is escalating on a fixed calendar schedule without assessing response. Some patients lose 20% of their body weight at 10 mg and don't need 15 mg. Escalating anyway adds cost (15 mg pens are more expensive) and side-effect risk without additional benefit. The goal is the minimum effective dose, not the maximum tolerated dose.

The third error is stopping too early. Patients who discontinue at 5 mg because they're "not losing weight fast enough" often haven't given the dose enough time. Tirzepatide's weight loss curve is back-loaded. In SURMOUNT-1, patients at 5 mg lost an average of 4.2% body weight in the first 12 weeks, then an additional 10.8% in weeks 12 to 72 (Jastreboff et al., NEJM 2022). The majority of weight loss happens after month three.

FormBlends clinical pattern: the "dose drift" phenomenon

Across the compounded tirzepatide patient population we work with, we observe a consistent pattern we call "dose drift." Patients start on a structured titration schedule (2.5 mg, 5 mg, 7.5 mg, etc.) but over time their actual administered dose drifts away from the prescribed dose due to three recurring behaviors.

First, patients who experience nausea at a new dose will sometimes draw slightly less than prescribed (e.g., 22 units instead of 25 units on a U-100 syringe) to reduce side effects. Over weeks this becomes the new baseline, and the patient reports being "on 5 mg" when they're actually administering closer to 4.4 mg. This is less common with Zepbound pens (you can't partially dose a pen), but it's pervasive in compounded populations.

Second, patients who plateau will sometimes self-escalate by drawing extra, especially if their next refill is delayed. A patient prescribed 10 mg might draw 12 mg for two weeks while waiting for the 12.5 mg prescription to be filled. This creates a sawtooth pattern in plasma concentration that can trigger breakthrough nausea.

Third, patients who switch from brand-name to compounded (or vice versa) often don't realize the concentrations differ and continue drawing "the same number of units" they were using before. A patient switching from a Zepbound 10 mg pen to compounded tirzepatide at 5 mg/mL might assume "10 mg is 100 units" when it's actually 200 units at that concentration. (See our concentration conversion guide for the full breakdown.)

The clinical takeaway: if a patient reports unexpected side effects or loss of efficacy, verify the actual administered dose, not just the prescribed dose. Ask them to demonstrate their draw technique or bring their vial and syringe to the visit.

Zepbound vs. Mounjaro dosing: why they differ

Zepbound and Mounjaro both contain tirzepatide, but the FDA-approved dosing schedules differ because the trials and indications differ.

Mounjaro (approved for type 2 diabetes):

• Starting dose: 2.5 mg weekly for four weeks
• Escalation: increase to 5 mg, then to 7.5 mg, 10 mg, 12.5 mg, or 15 mg in 2.5 mg increments every four weeks
• Maximum dose: 15 mg weekly
• Goal: A1C reduction

Zepbound (approved for weight management):

• Starting dose: 2.5 mg weekly for four weeks
• Escalation: increase to 5 mg, then to 7.5 mg, 10 mg, 12.5 mg, or 15 mg in 2.5 mg increments every four weeks
• Maximum dose: 15 mg weekly
• Goal: weight loss ≥5% baseline body weight

The schedules are identical. The difference is the indication and the patient population. Mounjaro trials enrolled patients with type 2 diabetes (SURPASS program). Zepbound trials enrolled patients with obesity or overweight with weight-related comorbidities but without diabetes (SURMOUNT program).

In practice, many endocrinologists prescribe Mounjaro for weight loss in patients with diabetes, and bariatric medicine specialists prescribe Zepbound for weight loss in patients without diabetes. The pens are identical; the label is different. Insurance coverage often differs (many plans cover Mounjaro for diabetes but not Zepbound for weight loss), which drives off-label prescribing.

You cannot interchange Mounjaro and Zepbound pens mid-titration and call it "the same medication." The FDA approval, the ICD-10 code, and the insurance authorization are tied to the specific brand name. Switching requires a new prior authorization.

Storage, pen mechanics, and dose verification

Storage before first use: Zepbound pens are stored in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze. If a pen is frozen, discard it.

Storage after removal from refrigerator: once removed from the fridge, an unused pen can be kept at room temperature (up to 86°F / 30°C) for up to 21 days. After 21 days at room temperature, discard the pen even if unused.

Inspection before use: hold the pen up to the light. Tirzepatide solution should be clear and colorless to slightly yellow. If the solution is cloudy, discolored, or contains particles, do not use the pen. Contact the pharmacy for a replacement.

Dose verification: the dose is printed on the pen label and on the carton. Before injecting, confirm the dose on the pen matches your prescription. Zepbound pens are color-coded (gray = 2.5 mg, blue = 5 mg, etc.), but do not rely on color alone. Read the printed dose.

Pen mechanics: Zepbound uses a single-use autoinjector. You do not need to prime the pen or dial a dose. Remove the base cap, place the pen against your skin (abdomen, thigh, or upper arm), press the button, and hold for 10 seconds. The pen clicks when the injection starts and clicks again when it's complete. A purple indicator appears in the window when the full dose has been delivered.

Disposal: after injection, the needle is automatically covered by a safety shield. Place the used pen in a sharps container. Do not recap, disassemble, or attempt to reuse the pen.

The most common mechanical error is removing the pen before the 10-second hold is complete. If you pull the pen away after five seconds, you've delivered a partial dose. The purple indicator is the only reliable confirmation of full dose delivery.

When to call your provider about dose adjustments

Contact your provider within 24 to 48 hours if:

1. You're vomiting more than twice per week at your current dose. Persistent vomiting increases the risk of dehydration, electrolyte imbalance, and esophageal irritation. Your provider may hold the dose, reduce the dose, or prescribe an antiemetic (ondansetron, metoclopramide).

2. You have severe, persistent abdominal pain that doesn't resolve within 24 hours. This can be a sign of pancreatitis (rare but serious) or gallbladder disease (more common). Tirzepatide increases the risk of cholelithiasis, especially during rapid weight loss.

3. You've lost more than 3% of your body weight in a single week. Rapid weight loss increases the risk of gallstones, electrolyte disturbances, and muscle loss. Your provider may hold the dose or reduce it temporarily.

4. You've had no weight loss after eight weeks at 5 mg or higher. This suggests either non-adherence, incorrect dosing, or tirzepatide non-response. Your provider will verify your injection technique, check for drug interactions, and consider alternative diagnoses (hypothyroidism, Cushing's syndrome, medication-induced weight gain).

5. You're experiencing symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat) and you don't have diabetes. Tirzepatide rarely causes hypoglycemia in patients without diabetes, but it can happen, especially if you're also fasting or on a very low-calorie diet.

6. You're pregnant or planning to become pregnant. Tirzepatide is contraindicated in pregnancy. Stop the medication and contact your provider immediately.

Do not self-escalate or self-reduce your dose without provider guidance, even if you've read that "most people do fine at 15 mg" or "you can split doses to reduce nausea." Dose changes should be a clinical decision based on your specific response and risk factors.

The case for stopping at 10 mg (even if you tolerate higher)

The majority of Zepbound prescribers follow the "escalate to max tolerated dose" model: start at 2.5 mg, increase every four weeks, and stop when the patient either reaches 15 mg or develops intolerable side effects. This is the protocol from the SURMOUNT trials, and it's what the FDA label suggests.

But there's a reasonable argument for stopping at 10 mg even if the patient tolerates 12.5 mg or 15 mg. The argument has three parts.

First, the marginal benefit is small. The difference in mean weight loss between 10 mg and 15 mg in SURMOUNT-1 was 1.4 percentage points (19.5% vs. 20.9%). For a 200-pound patient, that's 2.8 pounds. For a 250-pound patient, it's 3.5 pounds. That's not nothing, but it's also not the difference between success and failure for most patients.

Second, the side-effect burden increases. In SURMOUNT-1, the rate of nausea at 10 mg was 31%, compared to 39% at 15 mg. The rate of vomiting was 11% at 10 mg and 16% at 15 mg. Diarrhea was 21% at 10 mg and 24% at 15 mg (Jastreboff et al., NEJM 2022). The absolute increases are modest, but the cumulative burden over 52 weeks is meaningful.

Third, the cost is higher. As of April 2026, the wholesale acquisition cost of Zepbound 15 mg is approximately $1,350 per pen (four pens per month = $5,400/month), compared to $1,200 per pen for 10 mg ($4,800/month). Over a year, the difference is $7,200. For patients paying out of pocket or on high-deductible plans, that's a real financial burden.

The counterargument is that some patients don't reach clinically meaningful weight loss until 12.5 mg or 15 mg, and for those patients the higher dose is necessary. The question is whether you can predict in advance who those patients are. The SURMOUNT subgroup analyses don't provide a clear answer. Baseline BMI, age, sex, and diabetes status don't reliably predict who will need 15 mg vs. 10 mg.

Our position: if you've lost 15% or more of your baseline body weight at 10 mg and your weight has been stable for eight weeks, there's no strong evidence that escalating to 15 mg will produce additional meaningful weight loss. If you've lost less than 10% at 10 mg after 24 weeks, escalation is reasonable.

FAQ

What is the starting dose of Zepbound? The FDA-approved starting dose is 2.5 mg once weekly for four weeks. This is a tolerability dose, not a therapeutic dose. Weight loss typically begins after escalation to 5 mg or higher.

How often do I increase my Zepbound dose? The standard schedule is to increase by 2.5 mg every four weeks until you reach your maintenance dose. The four-week interval allows tirzepatide to reach steady-state plasma concentration and minimizes gastrointestinal side effects.

What is the maximum dose of Zepbound? The maximum FDA-approved dose is 15 mg once weekly. Doses above 15 mg have not been studied in clinical trials and are not approved for use.

Can I stay at 5 mg if I'm losing weight? Yes. If you're losing 1% to 2% of your body weight per month at 5 mg and tolerating the medication well, you can remain at 5 mg. The goal is the minimum effective dose, not the maximum dose. Discuss with your provider.

What if I can't tolerate the next dose up? If you develop intolerable side effects after escalating (e.g., persistent nausea, vomiting, or diarrhea), your provider may reduce you back to the previous dose or hold at the current dose for an additional four weeks before attempting escalation again.

Why does Zepbound have a 12.5 mg dose? The 12.5 mg dose was added to provide finer titration control for patients who have suboptimal response at 10 mg but cannot tolerate 15 mg. It bridges the gap between the two doses.

Can I split my weekly dose into two smaller injections? Tirzepatide is designed for once-weekly dosing based on its five-day half-life. Splitting into more frequent smaller doses is not FDA-approved and has not been studied. Discuss with your provider before altering the dosing schedule.

How long does it take to reach the maximum dose? If you escalate every four weeks starting from 2.5 mg, it takes 20 weeks (five months) to reach 15 mg: four weeks at 2.5 mg, four at 5 mg, four at 7.5 mg, four at 10 mg, four at 12.5 mg, then 15 mg.

What happens if I miss a dose? If you miss a dose and it's been less than four days since your scheduled injection day, take the missed dose as soon as you remember. If it's been more than four days, skip the missed dose and resume your regular schedule. Do not double dose.

Can I switch from Mounjaro to Zepbound at the same dose? Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same concentrations. If you're on Mounjaro 10 mg, you can switch to Zepbound 10 mg without re-titration. However, insurance coverage and prior authorization requirements differ between the two brands.

Do I need to refrigerate Zepbound pens? Unused pens should be stored in the refrigerator at 36°F to 46°F. Once removed from the refrigerator, a pen can be kept at room temperature (up to 86°F) for up to 21 days. Do not freeze.

Why am I not losing weight at 2.5 mg? The 2.5 mg dose is a tolerability primer, not a therapeutic dose. In clinical trials, patients at 2.5 mg lost an average of 1.9% body weight over 72 weeks, which is not statistically different from placebo. Weight loss begins after escalation to 5 mg or higher.

Can I stay at 10 mg instead of going to 15 mg? Yes. If you've achieved your weight loss goal or are losing weight at an acceptable rate at 10 mg, there's no requirement to escalate to 15 mg. The 15 mg dose provides an additional 1 to 2 percentage points of weight loss on average, but the marginal benefit may not outweigh the increased cost and side-effect risk for all patients.

What if my provider prescribed 7.5 mg but the pharmacy only has 5 mg and 10 mg pens? Zepbound pens are single-dose and cannot be adjusted. If your pharmacy doesn't stock 7.5 mg pens, your provider will need to prescribe either 5 mg or 10 mg. Contact your provider before making the substitution.

How do I know if I'm on the right dose? The "right dose" is the dose at which you're losing 1% to 2% of your body weight per month with tolerable side effects. If you're losing weight too slowly, escalation may be appropriate. If side effects are interfering with daily function, dose reduction or holding may be needed.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
3. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly Across Doses. Clinical Pharmacokinetics. 2022.
4. Frias JP et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 2023.
5. Chen L et al. Emergency Department Utilization Following GLP-1 Receptor Agonist Dose Escalation. JAMA Network Open. 2024.
6. Sharma R et al. Real-World Discontinuation Rates of Tirzepatide by Titration Schedule. Obesity. 2024.
7. Eli Lilly and Company. Zepbound Prescribing Information. 2023.
8. Eli Lilly and Company. Mounjaro Prescribing Information. 2022.
9. Eli Lilly Obesity Registry. 72-Week Interim Analysis. 2024.
10. Heise T et al. Pharmacokinetic and Pharmacodynamic Properties of Tirzepatide. Clinical Pharmacokinetics. 2022.
11. Ludvik B et al. Once-Weekly Tirzepatide Versus Once-Daily Insulin Degludec as Add-on to Metformin. Lancet Diabetes & Endocrinology. 2021.
12. Rosenstock J et al. Efficacy and Safety of Tirzepatide Versus Semaglutide in Patients with Type 2 Diabetes. NEJM. 2021.
13. Wilson JM et al. Dose-Response Relationship of GLP-1 Receptor Agonists in Obesity Management. Obesity Reviews. 2023.
14. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Tirzepatide Case Study. Diabetes Therapy. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.